These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25538314)

  • 1. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on!
    Genuth S
    Diabetes Care; 2015 Jan; 38(1):170-5. PubMed ID: 25538314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? Yes, they continue to serve us well!
    Abrahamson MJ
    Diabetes Care; 2015 Jan; 38(1):166-9. PubMed ID: 25538313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comment on Genuth. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on! Diabetes Care 2015;38:170-175.
    Schrijnders D; Houweling ST; Landman GW
    Diabetes Care; 2015 Jun; 38(6):e94. PubMed ID: 25998308
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to comment on Genuth. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on! Diabetes Care 2015;38:170-175.
    Genuth S
    Diabetes Care; 2015 Jun; 38(6):e95. PubMed ID: 25998309
    [No Abstract]   [Full Text] [Related]  

  • 5. Is It Time to Change the Type 2 Diabetes Treatment Paradigm? No! Metformin Should Remain the Foundation Therapy for Type 2 Diabetes.
    Inzucchi SE
    Diabetes Care; 2017 Aug; 40(8):1128-1132. PubMed ID: 28733378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm.
    Abdul-Ghani M; DeFronzo RA
    Diabetes Care; 2017 Aug; 40(8):1121-1127. PubMed ID: 28733377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
    Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Cardiovascular Safety of Sulfonylureas.
    Fernandez CJ; Raveendran AV; Htwe N
    Curr Drug Saf; 2021; 16(2):142-153. PubMed ID: 33243129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of glimepiride in the effective management of Type 2 diabetes.
    Davis SN
    J Diabetes Complications; 2004; 18(6):367-76. PubMed ID: 15531188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes.
    Lam KS; Chow CC; Tan KC; Ma RC; Kong AP; Tong PC; Tsang MW; Chan TM; Tang SC; Lee KK; So WY; Tomlinson B
    Curr Med Res Opin; 2016 Jun; 32(6):1097-108. PubMed ID: 26933918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study.
    Azoulay L; Schneider-Lindner V; Dell'aniello S; Schiffrin A; Suissa S
    Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):335-42. PubMed ID: 20052677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes.
    Montvida O; Shaw J; Atherton JJ; Stringer F; Paul SK
    Diabetes Care; 2018 Jan; 41(1):69-78. PubMed ID: 29109299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of sulfonylureas in the treatment of type 2 diabetes.
    Tomlinson B; Patil NG; Fok M; Chan P; Lam CWK
    Expert Opin Pharmacother; 2022 Feb; 23(3):387-403. PubMed ID: 34758676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.
    Berkowitz SA; Krumme AA; Avorn J; Brennan T; Matlin OS; Spettell CM; Pezalla EJ; Brill G; Shrank WH; Choudhry NK
    JAMA Intern Med; 2014 Dec; 174(12):1955-62. PubMed ID: 25347323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
    Göke R; Gruenberger JB; Bader G; Dworak M
    Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic approaches to improve blood glucose control in a patient with type 2 diabetes on a metformin-sulfonylurea combination].
    Scheen AJ; Paquot N
    Rev Med Liege; 2011 Apr; 66(4):215-21. PubMed ID: 21638841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial.
    Vaccaro O; Masulli M; Bonora E; Del Prato S; Giorda CB; Maggioni AP; Mocarelli P; Nicolucci A; Rivellese AA; Squatrito S; Riccardi G;
    Nutr Metab Cardiovasc Dis; 2012 Nov; 22(11):997-1006. PubMed ID: 23063367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles.
    Wurm R; Resl M; Neuhold S; Prager R; Brath H; Francesconi C; Vila G; Strunk G; Clodi M; Luger A; Pacher R; Hülsmann M
    Heart; 2016 Oct; 102(19):1544-51. PubMed ID: 27226327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
    Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
    Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.